BVS bioventus.com Company Net Income

Official company branding of bioventus.com (BVS)

Bioventus Inc. (BVS) develops orthopedic products through a hybrid asset-light model, combining proprietary research with outsourced manufacturing and a network of regional hubs. Historical price action, where the profit metric stands at 0.06, confirms the reliability of cash flows driven by the demand for tissue regeneration systems. Stable demand and an aging population place the company beyond market cycles, guaranteeing long-term growth.

BVS Bioventus Inc Net Income (07/04/2022 - 10/31/2026)

Financial and market metric breakdowns for Bioventus (BVS)

- market value and analyst target forecast:
Stock Price Bioventus Global|BVS - Price Target Chart
- market capitalization data:
Market Value Bioventus Global|BVS - Enterprise Value
- book capitalization indicators:
Net Assets per Share Bioventus|BVS - Company Net Assets|Market Capitalization to Net Assets bioventus.com|BVS - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital Bioventus Inc.|BVS - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Bioventus Inc|BVS - Company Total Debt|Debt to Net Assets Ratio Bioventus Global|BVS - Company Long-Term Debt|Company Current Liabilities Bioventus|Immediate Liquidity bioventus.com
- earnings and multiples data:
BVS - Net Profit
Summary company analysis:Bioventus Global (BVS)
Signature product of Bioventus Global

This indicator measures the bottom-line financial result after deducting all operating and tax liabilities. It reflects management's actual ability to generate value during periods of market stagnation. For Bioventus Inc. (BVS), such a metric confirms the efficiency of its asset-light model and the control over decentralized logistics. Steady growth validates the viability of the production outsourcing strategy. By analyzing the company's net income dynamics, an investor can assess the business's resilience to operational risks.

Main competitors

Boston Scientific Corporation Inc. (BSX) - Net Profit|Company Net Income Edwards Lifesciences|Company Net Income RMD|Net Profit PODD|Net Financial Result Zimmer Biomet Holdings|CooperVision - Net Income|ALGN (Align Corp) - Profit After Tax|Globus Medical, Inc. - Net Profit|Company Net Income TransMedics Group Inc|ATEC: Net Profit|Company Profit AORT|Net Income ENOV|IART: Final Profit|Company Net Income Establishment Labs (ESTA)|Net Income betabionics.com BBNX|Net Profit IRMD (IRADIMED)|Embecta Corp (EMBC) - Company Net Income|Tandem Diabetes - Net Profit|AXGN (Axogen Surgical) - Company Profit|SIBN: Net Profit|OFIX - Net Financial Result|KIDS (OrthoPediatrics Corp) - Net Profit|Net Income Treace Medical Concepts Inc (TMCI)|Net Profit SRTA|Net Profit Carlsmed Medical (CARL)|Company Net Income RxSight, Inc. RXST|ClearPoint Neuro Inc. - Company Net Income|STXS: Net Income|Final Profit STIM (Neuronetics Inc.)|SGHT: Net Profit|Company Net Income Orchestra BioMed Inc. (OBIO)|Company Net Income Anika Therapeutics Inc.|NSPR - Annual Net Income|Net Income ZJYL (Jin Medical International)|Net Profit vivani.com (VANI)|Net Profit XTNT (Xtant Medical)|Net Financial Result NeuroOne Medical Technologies Corp. (NMTC)|MODD - Company Net Income|Profit After Tax MYO|Envoy Medical (COCH) - Company Net Income|Net Income Vivos Therapeutics Inc.|NVNO (enVVeno) - Net Profit|Company Net Income SINTX Technologies SINT|Company Net Income Tenon Medical, Inc. (TNON)|rewalk.com - Company Profit|Autonomix Medical - Net Income|Profit After Payment of Taxes IVF (INVO Bioscience)|Bone Biologics Corporation - Net Profit|AXNX: Company Net Income|BIOL: Net Profit|DYNT - Net Financial Result|Company Net Income Paragon 28 Inc.|Company Net Income INVO Bio INVO